Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 7/20 | 0.65 |
| ▸ | NTRK3 | Q16288 | 5/20 | 0.65 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.57 |
| ▸ | CDK2 | P24941 | 11/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.57 |
| ▸ | PRKCB | P05771 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982228 | 0.95 | NTRK1 (0.60) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL3484824 | 0.89 | NTRK1 (0.66) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL3484823 | 0.88 | NTRK1 (0.78) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL1984103 | 0.88 | NTRK1 (0.70) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL1987061 | 0.88 | NTRK1 (0.61) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL1984801 | 0.87 | NTRK1 (0.70) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL3485283 | 0.85 | NTRK1 (0.69) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL3485445 | 0.85 | NTRK1 (0.60) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL3485846 | 0.85 | NTRK1 (0.65) | NTRK1NTRK3NTRK2CCNA2CDK2 | |
| SCHEMBL3485984 | 0.84 | CCNA2 (0.69) | NTRK1NTRK3NTRK2CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227472-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-07-24 | — | — | US | claimed |
| EP-2089394-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2011-06-29 | — | — | EP | claimed |
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-14 | — | — | US | claimed |
| EP-2089394-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2009-08-19 | — | — | EP | claimed |
| WO-2008043745-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-04-17 | — | — | WO | claimed |
| US-8623876-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-07 | — | — | US | disclosed |
| US-20120277248-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-01 | — | — | US | disclosed |
| US-8227472-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-07-24 | — | — | US | disclosed |
| EP-2089394-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-14 | — | — | US | disclosed |
| EP-2089394-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008043745-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K3, MAP3K15 | NTRK1 1290/4885NTRK3 1078/4885NTRK2 2021/4885 |
| US-20120277248-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K3, MAP3K15 | NTRK1 1290/4885NTRK3 1078/4885NTRK2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.